EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alpha Cognition's enterprise value is C$108.03 Mil.
Alpha Cognition's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$-18.32 Mil. Therefore, Alpha Cognition's EV-to-EBITDA for today is -5.90.
The historical rank and industry rank for Alpha Cognition's EV-to-EBITDA or its related term are showing as below:
XCNQ:ACOG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -504.71 Med: 0 Max: 905.48
Current: -5.9
During the past 4 years, the highest EV-to-EBITDA of Alpha Cognition was 905.48. The lowest was -504.71. And the median was 0.00.
XCNQ:ACOG's EV-to-EBITDA is ranked worse than 100% of 460
companies
in the Biotechnology industry
Industry Median: 9.53
vs XCNQ:ACOG: -5.90
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Alpha Cognition EV-to-EBITDA Historical Data
The historical data trend for Alpha Cognition's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alpha Cognition's EV-to-EBITDA
For the Biotechnology subindustry, Alpha Cognition's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Cognition's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Cognition's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alpha Cognition's EV-to-EBITDA falls into.
Alpha Cognition's current Enterprise Value is C$108.03 Mil.
Alpha Cognition's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-18.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Alpha Cognition's PE Ratio for today is calculated as:
Alpha Cognition's share price for today is C$0.69.
Alpha Cognition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.188.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Alpha Cognition's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XCNQ:ACOG has been successfully added to your 